FDA Approves the First Pediatric Gene Therapy for MPS IIIA

A monumental milestone for children and families impacted by Sanfilippo syndrome Type A (MPS IIIA): The FDA has granted full approval to FAYUVI™ (rebisufligene etisparvovec-hopf), the first-ever pediatric gene therapy for this fatal, ultra-rare neurodegenerative condition.